FDA Warns About Amputation Risk With CanagliflozinFDA Warns About Amputation Risk With Canagliflozin

The agency is investigating whether the two-fold increase in amputations seen in an ongoing trial is attributable to the drug. News Alerts
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Alert Source Type: news